Business Context and Reporting Period
Company: Daré Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2023
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued: 10,000,000 shares of common stock and warrants to purchase 10,000,000 shares.
- Offering Price: $0.70 per share of common stock and accompanying warrant.
- Gross Proceeds: Expected $7.0 million (before expenses and excluding warrant exercise proceeds).
- Warrant Terms:
- Exercise Price: $0.77 per share.
- Term: 5.5 years from issuance.
- Exercise Period: Commences 6 months after issuance.
- Ownership Limit: 4.99% (or 9.99% at holder election) of outstanding common stock.
Operational Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change is the execution of a securities purchase agreement with two institutional investors. This represents a dilution event and an increase in cash assets upon closing. The filing does not provide comparative financial data to assess changes in revenue or profitability versus prior periods.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: Daré intends to use the net proceeds for general corporate purposes, specifically including:
- Clinical trials.
- Research and development activities.
- General and administrative costs.
- Meeting working capital needs.
Closing Date: Expected on or about September 1, 2023, subject to customary closing conditions.
Risks and Contingencies: The offering is subject to customary closing conditions. The filing includes standard legal disclaimers regarding the legality of the issuance and the non-offer nature of the report in jurisdictions where registration is not complete.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds after deducting offering expenses.
- Confirm the post-offering share count to assess the dilution impact on existing shareholders.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and redemption rights.
- Monitor the company's cash runway extension relative to the $7.0 million gross proceeds.
- Check for any subsequent filings regarding the exercise of warrants or changes in the 4.99% ownership limitation.